Wanjia Group (00401.HK) Hot Stock Analysis Report

Wanjia Group (00401.HK) is a healthcare/biotechnology company listed on the Hong Kong Stock Exchange, with main businesses including hemodialysis services and pharmaceutical wholesale distribution [1]. As of December 10, 2025, the company’s stock closed at HK$0.120, rising 3.5% that day and entering the Hong Kong Stock Surge List on the East Money App, becoming a hot stock [1]. However, searches from December 25 to 30, 2025, found no major breaking news, financial report releases, or regulatory announcements that directly drove it to become popular [2][3].

In terms of price and trading volume, the company’s stock fell 9.231% to HK$0.118 on December 8, 2025, followed by a rebound; the trading volume on December 10 was only HK$12,000, indicating extremely low market participation [1]. Due to data access limitations, price and trading volume data from December 15 to 30, 2025, are temporarily unavailable [0].

Market attention to Wanjia Group (00401.HK) is mainly driven by speculative trading. The company’s fundamentals are weak; the interim report as of September 30, 2025, shows that the operating loss attributable to shareholders was HK$712,000, turning from a profit of HK$125,600 in the same period last year to a loss [1]. At the same time, the company’s indirectly non-wholly-owned subsidiary had its medical insurance service agreement suspended for 61 days due to prescription management violations, posing regulatory risks [1]. The extremely low trading volume (HK$12,000) indicates that price fluctuations may be driven by a small number of speculative transactions, lacking broad market participation [1].

1. Financial Risk
   : Interim results turned to loss, with weak revenue growth [1].
2. Regulatory Risk
   : The suspension of the medical insurance service agreement may affect the company’s business [1].
3. Liquidity Risk
   : Extremely low trading volume leads to insufficient liquidity, and prices are susceptible to speculative trading [1].

• If the suspension of the medical insurance service agreement is properly resolved, regulatory risks may be mitigated.
• If future financial reports show improved profitability, market confidence may be boosted.

Wanjia Group (00401.HK) became a hot stock mainly due to short-term price fluctuations, lacking major substantive driving events. The company faces financial, regulatory, and liquidity risks, with market sentiment dominated by speculative trading. Investors should pay attention to the follow-up progress of the medical insurance service agreement suspension, the profitability of future financial reports, and changes in trading volume.